{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:25:14Z","timestamp":1786980314442,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,17]]},"DOI":"10.7759\/cureus.114659","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:33:00Z","timestamp":1786977180000},"source":"Crossref","is-referenced-by-count":0,"title":["Trifarotene for Facial and Truncal Acne Vulgaris: A Narrative Review of Clinical Trial Evidence"],"prefix":"10.7759","author":[{"given":"Jordan P","family":"Krawchuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Tamucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13462","article-title":"A global perspective on the epidemiology of acne","volume":"172 Suppl 1","author":"Tan JK","year":"2015","unstructured":"Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015, 172 Suppl 1:3-12. 10.1111\/bjd.13462","journal-title":"Br J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-018-0558-5","article-title":"Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris","volume":"6","author":"O'Neill AM","year":"2018","unstructured":"O'Neill AM, Gallo RL. Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris. Microbiome. 2018, 6:177. 10.1186\/s40168-018-0558-5","journal-title":"Microbiome"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/njcp.njcp_86_20","article-title":"Internalized stigma in acne vulgaris and its relationship with quality of life, general health, body perception, and depression","volume":"23","author":"Kotekoglu D","year":"2020","unstructured":"Kotekoglu D, Parlakdag A, Koramaz FS, et al.. Internalized stigma in acne vulgaris and its relationship with quality of life, general health, body perception, and depression. Niger J Clin Pract. 2020, 23:1289-94. 10.4103\/njcp.njcp_86_20","journal-title":"Niger J Clin Pract"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein AL","year":"2016","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, et al.. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016, 74:945-73.e33. 10.1016\/j.jaad.2015.12.037","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.044","article-title":"Randomized phase 3 evaluation of trifarotene 50\u00a0\u03bcg\/g cream treatment of moderate facial and truncal acne","volume":"80","author":"Tan J","year":"2019","unstructured":"Tan J, Thiboutot D, Popp G, et al.. Randomized phase 3 evaluation of trifarotene 50\u00a0\u03bcg\/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019, 80:1691-9. 10.1016\/j.jaad.2019.02.044","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2018.04.036","article-title":"Structure-based design of Trifarotene (CD5789), a potent and selective RAR\u03b3 agonist for the treatment of acne","volume":"28","author":"Thoreau E","year":"2018","unstructured":"Thoreau E, Arlabosse JM, Bouix-Peter C, et al.. Structure-based design of Trifarotene (CD5789), a potent and selective RAR\u03b3 agonist for the treatment of acne. Bioorg Med Chem Lett. 2018, 28:1736-41. 10.1016\/j.bmcl.2018.04.036","journal-title":"Bioorg Med Chem Lett"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16719","article-title":"Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-\u03b3 agonist trifarotene","volume":"179","author":"Aubert J","year":"2018","unstructured":"Aubert J, Piwnica D, Bertino B, et al.. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-\u03b3 agonist trifarotene. Br J Dermatol. 2018, 179:442-56. 10.1111\/bjd.16719","journal-title":"Br J Dermatol"},{"key":"ref8","unstructured":"Galderma receives FDA approval for AKLIEF\u00ae (trifarotene) cream, 0.005%, the first new retinoid molecule for the treatment of acne in over 20 years. (2019). Accessed. July 26, 2026: https:\/\/www.galderma.com\/news\/galderma-receives-fda-approval-akliefr-trifarotene-cream-0005-first-new-retinoid-molecule."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1504303","article-title":"Trifarotene: a novel therapeutic option for acne","volume":"2022","author":"Naik PP","year":"2022","unstructured":"Naik PP. Trifarotene: a novel therapeutic option for acne. Dermatol Res Pract. 2022, 2022:1504303. 10.1155\/2022\/1504303","journal-title":"Dermatol Res Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17189","article-title":"Importance of treating acne sequelae in skin of color: 6-month phase IV study of trifarotene with an appropriate skincare routine including UV protection in acne-induced post-inflammatory hyperpigmentation","volume":"63","author":"Alexis A","year":"2024","unstructured":"Alexis A, Del Rosso JQ, Forman S, et al.. Importance of treating acne sequelae in skin of color: 6-month phase IV study of trifarotene with an appropriate skincare routine including UV protection in acne-induced post-inflammatory hyperpigmentation. Int J Dermatol. 2024, 63:806-15. 10.1111\/ijd.17189","journal-title":"Int J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis","volume":"18","author":"Haddaway NR","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev. 2022, 18:e1230. 10.1002\/cl2.1230","journal-title":"Campbell Syst Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15794","article-title":"Long-term safety and efficacy of trifarotene 50\u00a0\u03bcg\/g cream, a first-in-class RAR-\u03b3 selective topical retinoid, in patients with moderate facial and truncal acne","volume":"34","author":"Blume-Peytavi U","year":"2020","unstructured":"Blume-Peytavi U, Fowler J, Kem\u00e9ny L, et al.. Long-term safety and efficacy of trifarotene 50\u00a0\u03bcg\/g cream, a first-in-class RAR-\u03b3 selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2020, 34:166-73. 10.1111\/jdv.15794","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref13","article-title":"A randomized, controlled trial of trifarotene plus doxycycline for severe acne vulgaris","volume":"15","author":"Del Rosso JQ","year":"2022","unstructured":"Del Rosso JQ, Johnson SM, Schlesinger T, et al.. A randomized, controlled trial of trifarotene plus doxycycline for severe acne vulgaris. J Clin Aesthet Dermatol. 2022, 15:E53-9.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01042-7","article-title":"Trifarotene reduces risk for atrophic acne scars: results from a phase 4 controlled study","volume":"13","author":"Schleicher S","year":"2023","unstructured":"Schleicher S, Moore A, Rafal E, et al.. Trifarotene reduces risk for atrophic acne scars: results from a phase 4 controlled study. Dermatol Ther (Heidelb). 2023, 13:3085-96. 10.1007\/s13555-023-01042-7","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1977.tb00840.x","article-title":"Cyclandelate in the treatment of senile mental changes: a double-blind evaluation","volume":"25","author":"Rao DB","year":"1977","unstructured":"Rao DB, Georgiev EL, Paul PD, Guzman AB. Cyclandelate in the treatment of senile mental changes: a double-blind evaluation. J Am Geriatr Soc. 1977, 25:548-51. 10.1111\/j.1532-5415.1977.tb00840.x","journal-title":"J Am Geriatr Soc"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0098-5","article-title":"New patient-oriented tools for assessing atrophic acne scarring","volume":"6","author":"Layton A","year":"2016","unstructured":"Layton A, Dr\u00e9no B, Finlay AY, et al.. New patient-oriented tools for assessing atrophic acne scarring. Dermatol Ther (Heidelb). 2016, 6:219-33. 10.1007\/s13555-016-0098-5","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.017","article-title":"Reliability assessment and validation of the postacne hyperpigmentation index (PAHPI), a new instrument to measure postinflammatory hyperpigmentation from acne vulgaris","volume":"70","author":"Savory","year":"2014","unstructured":"Savory, S. A., Agim, N. G., Mao, R.,. Reliability assessment and validation of the postacne hyperpigmentation index (PAHPI), a new instrument to measure postinflammatory hyperpigmentation from acne vulgaris. Journal of the American Academy of Dermatology. 2014, 70:108-114. 10.1016\/j.jaad.2013.09.017","journal-title":"Journal of the American Academy of Dermatology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","unstructured":"Finlay, A. Y., & Khan, G. K. . Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clinical and Experimental Dermatology. 1994, 19:210-216. 10.1111\/j.1365-2230.1994.tb01167.x","journal-title":"Clinical and Experimental Dermatology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","article-title":"The Children\u2019s Dermatology Life Quality Index (CDLQI): initial validation and practical use","volume":"132(6)","author":"Lewis-Jones","year":"1995","unstructured":"Lewis-Jones, M. S., & Finlay, A. Y. . The Children\u2019s Dermatology Life Quality Index (CDLQI): initial validation and practical use. British Journal of Dermatology. 1995, 132(6):942-949. 10.1111\/j.1365-2133.1995.tb16953.x","journal-title":"British Journal of Dermatology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/bf00540020","article-title":"Evaluating health-related quality of life in patients with facial acne: development of a self-administered questionnaire for clinical trials","volume":"5(5)","author":"Girman","year":"1996","unstructured":"Girman, C. J., Hartmaier, S., Thiboutot, D.,. Evaluating health-related quality of life in patients with facial acne: development of a self-administered questionnaire for clinical trials. Quality of Life Research, an international journal of quality of life aspects of treatment, care and rehabilitation. 1996, 5(5):481-490. 10.1007\/bf00540020","journal-title":"Quality of Life Research, an international journal of quality of life aspects of treatment, care and rehabilitation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/521755-trifarotene-for-facial-and-truncal-acne-vulgaris-a-narrative-review-of-clinical-trial-evidence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:33:01Z","timestamp":1786977181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/521755-trifarotene-for-facial-and-truncal-acne-vulgaris-a-narrative-review-of-clinical-trial-evidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.114659","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}